Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 14 02 2022
accepted: 13 04 2022
pubmed: 21 5 2022
medline: 30 6 2022
entrez: 20 5 2022
Statut: ppublish

Résumé

The optimal management of the urethra in patients planned for radical cystectomy (RC) remains unclear. We sought to evaluate the impact of urethrectomy on perioperative and oncological outcomes in patients treated with RC for non-metastatic urothelial carcinoma of the bladder (UCB). We assessed the retrospective data from patients treated with RC for UCB of five European University Hospitals. Associations of urethrectomy with progression-free (PFS), cancer-free (CSS), and overall (OS) survivals were assessed in univariable and multivariable Cox regression models. We performed a subgroup analysis in patients at high risk for urethral recurrence (UR) (urethral invasion and/or bladder neck invasion and/or multifocality and/or prostatic urethra involvement). A total of 887 non-metastatic UCB patients were included. Among them, 146 patients underwent urethrectomy at the time of RC. Urethrectomy was performed more often in patients with urethral invasion, T3/4 tumor stage, CIS, positive frozen section analysis of the urethra, and those who received neoadjuvant chemotherapy, underwent robotic RC, and/or received an ileal conduit urinary diversion (all p < 0.001). Estimated blood loss and the postoperative complication rate were comparable between patients who received an urethrectomy and those who did not. Urethrectomy during RC was not associated with PFS (HR 0.83, p = 0.17), CSS (HR 0.93, p = 0.67), or OS (HR 1.08, p = 0.58). In the subgroup of 276 patients at high risk for UR, urethrectomy at the time of RC decreased the risk of progression (HR 0.58, p = 0.04). In our study, urethrectomy at the time of RC seems to benefit only patients at high risk for UR. Adequate risk assessment of UCB patients' history may allow for better clinical decision-making and patient counseling.

Identifiants

pubmed: 35596017
doi: 10.1007/s00345-022-04025-z
pii: 10.1007/s00345-022-04025-z
pmc: PMC9236994
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1689-1696

Informations de copyright

© 2022. The Author(s).

Références

Gakis G et al (2017) Systematic review on the fate of the remnant urothelium after radical cystectomy. Eur Urol. https://doi.org/10.1016/j.eururo.2016.09.035
doi: 10.1016/j.eururo.2016.09.035 pubmed: 27916203
Chang SS et al (2020) Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guidelines (amended 2020). J Urol. https://doi.org/10.1016/j.juro.2017.04.086
doi: 10.1016/j.juro.2017.04.086 pubmed: 33356478 pmcid: 8112465
Laukhtina E et al (2021) Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer : a systematic review and meta-analysis. Urol Oncol Semin Orig Investig 39:806–815. https://doi.org/10.1016/j.urolonc.2021.06.009
doi: 10.1016/j.urolonc.2021.06.009
Witjes JA et al (2020) EAU-ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multistakeholder effort† [formula presented]: under the auspices of the EAU-ESMO guidelines committees. Eur Urol. https://doi.org/10.1016/j.eururo.2019.09.035
doi: 10.1016/j.eururo.2019.09.035 pubmed: 32978014 pmcid: 7183974
Witjes JA et al (2022) EAU guidelines on muscle-invasive and metastatic bladder cancer. In: EAU guidelines. 2022
Spiess PE et al (2006) Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology 67(3):466–471. https://doi.org/10.1016/j.urology.2005.09.043
doi: 10.1016/j.urology.2005.09.043 pubmed: 16527559
Hakozaki K et al (2021) Significance of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer. Jpn J Clin Oncol 51(2):287–295. https://doi.org/10.1093/jjco/hyaa168
doi: 10.1093/jjco/hyaa168 pubmed: 32893303
Nelles JL, Konety BR, Saigal C, Pace J, Lai J (2008) Urethrectomy following cystectomy for bladder cancer in men: practice patterns and impact on survival. J Urol 180(5):1933–1937. https://doi.org/10.1016/j.juro.2008.07.039
doi: 10.1016/j.juro.2008.07.039 pubmed: 18801516 pmcid: 2643351
Shariat SF et al (2007) Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 51(1):152–160. https://doi.org/10.1016/j.eururo.2006.08.037
doi: 10.1016/j.eururo.2006.08.037 pubmed: 17011114
Novara G et al (2010) Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 183(6):2165–2170. https://doi.org/10.1016/j.juro.2010.02.021
doi: 10.1016/j.juro.2010.02.021 pubmed: 20399473
Rink M et al (2012) Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. Eur Urol. https://doi.org/10.1016/j.eururo.2011.12.055
doi: 10.1016/j.eururo.2011.12.055 pubmed: 23273681 pmcid: 4378834
Li X, Wang W, Zhu G, He W, Gou X (2018) Risk factors, follow-up, and treatment of urethral recurrence following radical cystectomy and urinary diversion for bladder cancer : a meta-analysis of 9498 patients. Oncotarget 9(2):2782–2796
doi: 10.18632/oncotarget.23451
Coutts A, Grigor K, Fowler J (1985) Urethral dysplasia and bladder cancer in cystectomy specimens. Br J Urol 57(5):535–541. https://doi.org/10.1111/j.1464-410X.1985.tb05862.x
doi: 10.1111/j.1464-410X.1985.tb05862.x pubmed: 4063735
Elshal AM, Barakat TS, Mosbah A, Abdel-Latif M, Abol-Enein H (2011) Complications of radical cysto-urethrectomy using modified Clavien grading system: prepubis versus perineal urethrectomy. BJU Int 108(8):1297–1300. https://doi.org/10.1111/j.1464-410X.2010.09987.x
doi: 10.1111/j.1464-410X.2010.09987.x pubmed: 21352465
Joniau S, Shabana W, Verlinde B, Van Poppel H (2007) Prepubic urethrectomy during radical cystoprostatectomy. Eur Urol 51(4):915–921. https://doi.org/10.1016/j.eururo.2006.09.046
doi: 10.1016/j.eururo.2006.09.046 pubmed: 17069962
Labbate C, Werntz RP, Adamic B, Steinberg GD (2019) The impact of omission of intraoperative frozen section prior to orthotopic neobladder reconstruction. J Urol 202(4):763–768. https://doi.org/10.1097/JU.0000000000000317
doi: 10.1097/JU.0000000000000317 pubmed: 31059666
Laukhtina E et al (2021) Accuracy of frozen section analysis of urethral and ureteral margins during radical cystectomy for bladder cancer: a systematic review and diagnostic meta-analysis. Eur Urol Focus. https://doi.org/10.1016/j.euf.2021.05.010
doi: 10.1016/j.euf.2021.05.010 pubmed: 34563481
Stein J, Penson D, Wu S, Skinner D (2007) Pathological guidelines for orthotopic urinary diversion in women with bladder cancer: a review of the literature. J Urol 178(3):756–760. https://doi.org/10.1016/j.juro.2007.05.013
doi: 10.1016/j.juro.2007.05.013 pubmed: 17631333
Nieder AM, Sved PD, Gomez P, Kim SS, Manoharan M, Soloway MS (2004) Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring. Urology. https://doi.org/10.1016/j.urology.2004.06.012
doi: 10.1016/j.urology.2004.06.012 pubmed: 15533484

Auteurs

Ekaterina Laukhtina (E)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Axelle Boehm (A)

Department of Urology, University Hospital of Tours, Tours, France.

Benoit Peyronnet (B)

Department of Urology, University Hospital of Rennes, Rennes, France.

Carlo Andrea Bravi (CA)

Unit of Urology, Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.
Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Melle, Belgium.

Jose Batista Da Costa (J)

Department of Urology, University Hospital Henri Mondor, AP-HP, UPEC, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, 95010, Créteil Cedex, France.

Francesco Soria (F)

Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Turin, Italy.

David D'Andrea (D)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Pawel Rajwa (P)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Department of Urology, Medical University of Silesia, Zabrze, Poland.

Fahad Quhal (F)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Takafumi Yanagisawa (T)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

Frederik König (F)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Department of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

Hadi Mostafaei (H)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Dmitry Enikeev (D)

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Alexandre Ingels (A)

Department of Urology, University Hospital Henri Mondor, AP-HP, UPEC, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, 95010, Créteil Cedex, France.

Gregory Verhoest (G)

Department of Urology, University Hospital of Rennes, Rennes, France.

Frederiek D'Hondt (F)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Melle, Belgium.

Alexandre Mottrie (A)

Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium.
ORSI Academy, Melle, Belgium.

Steven Joniau (S)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Hendrik Van Poppel (H)

Department of Urology, University Hospitals Leuven, Leuven, Belgium.

Alexandre de la Taille (A)

Department of Urology, University Hospital Henri Mondor, AP-HP, UPEC, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, 95010, Créteil Cedex, France.

Karim Bensalah (K)

Department of Urology, University Hospital of Rennes, Rennes, France.

Franck Bruyère (F)

Department of Urology, University Hospital of Tours, Tours, France.

Shahrokh F Shariat (SF)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria.
Department of Urology, Weill Cornell Medical College, New York, NY, USA.
Department of Urology, University of Texas Southwestern, Dallas, TX, USA.
Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.
Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.

Benjamin Pradere (B)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. benjaminpradere@gmail.com.
Department of Urology, La Croix Du Sud Hospital, Quint Fonsegrives, France. benjaminpradere@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH